---
document_datetime: 2025-12-02 04:59:14
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/silodosin-recordati.html
document_name: silodosin-recordati.html
version: success
processing_time: 0.1288917
conversion_datetime: 2025-12-24 15:27:04.667064
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Silodosin Recordati

[RSS](/en/individual-human-medicine.xml/67167)

##### Authorised

This medicine is authorised for use in the European Union

silodosin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Silodosin Recordati](#news-on)
- [More information on Silodosin Recordati](#more-information-on-silodosin-recordati-1550)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Silodosin Recordati is a medicine used to treat the symptoms of benign prostatic hyperplasia (BPH, an enlarged prostate gland) in adults. The prostate gland is an organ found at the base of the bladder in men. When enlarged, it can cause problems with the flow of urine.

This medicine is identical to Urorec, which has been authorised in the EU since 29 January 2010.

Expand section

Collapse section

## How is Silodosin Recordati used?

Silodosin Recordati can only be obtained with a prescription and is available as capsules (4 and 8 mg). The recommended dose is one 8 mg capsule once a day. For men with moderate kidney problems, the starting dose should be 4 mg once a day. This may be increased to 8 mg once a day after a week. Silodosin Recordati is not recommended for patients with severe kidney problems.

The capsules should be taken with food, preferably at the same time every day. For more information about using Silodosin Recordati, see the package leaflet or contact your doctor or pharmacist.

## How does Silodosin Recordati work?

The active substance in Silodosin Recordati, silodosin, is an alpha-adrenoreceptor antagonist. It works by blocking receptors (targets) called alpha1A adrenoreceptors in the prostate gland, the bladder and the urethra (the tube that leads from the bladder to the outside of the body). When these receptors are activated, they cause the muscles controlling the flow of urine to contract. By blocking these receptors, silodosin allows these muscles to relax, making it easier to pass urine and relieving the symptoms of BPH.

## What benefits of Silodosin Recordati have been shown in studies?

Three main studies in over 1,800 men showed that Silodosin Recordati was effective at reducing symptoms of BPH, such as problems with urinating.

The symptoms were measured using the international prostate symptom score (IPSS). In two of the studies the IPSS was around 21 points at the start of the study. After 12 weeks, the IPSS fell by 6.4 points in the men who took Silodosin Recordati compared with 3.5 points in the men who took placebo (a dummy treatment). In the third study, the IPSS was around 19 points before treatment and fell by 7 points with Silodosin Recordati compared with 6.7 points in men who took tamsulosin (another medicine used for BPH) and 4.7 points with placebo.

## What are the risks associated with Silodosin Recordati?

The most common side effect with Silodosin Recordati (which may affect more than 1 in 10 people) is a reduction in the amount of semen released during ejaculation. Intra operative floppy iris syndrome (IFIS) occurs in some patients taking alpha adrenoreceptor antagonists and may lead to complications during cataract surgery. IFIS is a condition that makes the iris floppy. For the full list of side effects and restrictions of Silodosin Recordati, see the package leaflet.

## Why is Silodosin Recordati authorised in the EU?

Silodosin Recordati is effective at reducing problems with urinating in men with BPH and its side effects are comparable to those seen with other medicines of the same class. The European Medicines Agency therefore decided that Silodosin Recordati's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Silodosin Recordati?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Silodosin Recordati have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Silodosin Recordati are continuously monitored. Side effects reported with Silodosin Recordati are carefully evaluated and any necessary action taken to protect patients.

## Other information about Silodosin Recordati

Silodosin Recordati received a marketing authorisation valid throughout the EU on 7 January 2019.

Silodosin Recordati : EPAR - Medicine overview

Reference Number: EMA/815843/2018

English (EN) (72.84 KB - PDF)

**First published:** 22/01/2019

[View](/en/documents/overview/silodosin-recordati-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-375)

български (BG) (100.77 KB - PDF)

**First published:**

22/01/2019

[View](/bg/documents/overview/silodosin-recordati-epar-medicine-overview_bg.pdf)

español (ES) (82 KB - PDF)

**First published:**

22/01/2019

[View](/es/documents/overview/silodosin-recordati-epar-medicine-overview_es.pdf)

čeština (CS) (96.83 KB - PDF)

**First published:**

22/01/2019

[View](/cs/documents/overview/silodosin-recordati-epar-medicine-overview_cs.pdf)

dansk (DA) (72.1 KB - PDF)

**First published:**

22/01/2019

[View](/da/documents/overview/silodosin-recordati-epar-medicine-overview_da.pdf)

Deutsch (DE) (73.16 KB - PDF)

**First published:**

22/01/2019

[View](/de/documents/overview/silodosin-recordati-epar-medicine-overview_de.pdf)

eesti keel (ET) (71.73 KB - PDF)

**First published:**

22/01/2019

[View](/et/documents/overview/silodosin-recordati-epar-medicine-overview_et.pdf)

ελληνικά (EL) (108.48 KB - PDF)

**First published:**

22/01/2019

[View](/el/documents/overview/silodosin-recordati-epar-medicine-overview_el.pdf)

français (FR) (81.82 KB - PDF)

**First published:**

22/01/2019

[View](/fr/documents/overview/silodosin-recordati-epar-medicine-overview_fr.pdf)

hrvatski (HR) (94.16 KB - PDF)

**First published:**

22/01/2019

[View](/hr/documents/overview/silodosin-recordati-epar-medicine-overview_hr.pdf)

italiano (IT) (82.99 KB - PDF)

**First published:**

22/01/2019

[View](/it/documents/overview/silodosin-recordati-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (100.65 KB - PDF)

**First published:**

22/01/2019

[View](/lv/documents/overview/silodosin-recordati-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (93.9 KB - PDF)

**First published:**

22/01/2019

[View](/lt/documents/overview/silodosin-recordati-epar-medicine-overview_lt.pdf)

magyar (HU) (91.23 KB - PDF)

**First published:**

22/01/2019

[View](/hu/documents/overview/silodosin-recordati-epar-medicine-overview_hu.pdf)

Malti (MT) (97.35 KB - PDF)

**First published:**

22/01/2019

[View](/mt/documents/overview/silodosin-recordati-epar-medicine-overview_mt.pdf)

Nederlands (NL) (72.17 KB - PDF)

**First published:**

22/01/2019

[View](/nl/documents/overview/silodosin-recordati-epar-medicine-overview_nl.pdf)

polski (PL) (97.98 KB - PDF)

**First published:**

22/01/2019

[View](/pl/documents/overview/silodosin-recordati-epar-medicine-overview_pl.pdf)

português (PT) (72.12 KB - PDF)

**First published:**

22/01/2019

[View](/pt/documents/overview/silodosin-recordati-epar-medicine-overview_pt.pdf)

română (RO) (94.44 KB - PDF)

**First published:**

22/01/2019

[View](/ro/documents/overview/silodosin-recordati-epar-medicine-overview_ro.pdf)

slovenčina (SK) (96.32 KB - PDF)

**First published:**

22/01/2019

[View](/sk/documents/overview/silodosin-recordati-epar-medicine-overview_sk.pdf)

slovenščina (SL) (91.43 KB - PDF)

**First published:**

22/01/2019

[View](/sl/documents/overview/silodosin-recordati-epar-medicine-overview_sl.pdf)

Suomi (FI) (71.57 KB - PDF)

**First published:**

22/01/2019

[View](/fi/documents/overview/silodosin-recordati-epar-medicine-overview_fi.pdf)

svenska (SV) (72.28 KB - PDF)

**First published:**

22/01/2019

[View](/sv/documents/overview/silodosin-recordati-epar-medicine-overview_sv.pdf)

Silodosin Recordati : EPAR - Risk-management-plan summary

English (EN) (50.16 KB - PDF)

**First published:** 22/01/2019

[View](/en/documents/rmp-summary/silodosin-recordati-epar-risk-management-plan-summary_en.pdf)

## Product information

Silodosin Recordati : EPAR - Product information

English (EN) (412.87 KB - PDF)

**First published:** 22/01/2019

**Last updated:** 10/03/2025

[View](/en/documents/product-information/silodosin-recordati-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-510)

български (BG) (507.08 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/bg/documents/product-information/silodosin-recordati-epar-product-information_bg.pdf)

español (ES) (421.96 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/es/documents/product-information/silodosin-recordati-epar-product-information_es.pdf)

čeština (CS) (493.01 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/cs/documents/product-information/silodosin-recordati-epar-product-information_cs.pdf)

dansk (DA) (410.88 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/da/documents/product-information/silodosin-recordati-epar-product-information_da.pdf)

Deutsch (DE) (428.59 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/de/documents/product-information/silodosin-recordati-epar-product-information_de.pdf)

eesti keel (ET) (429.35 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/et/documents/product-information/silodosin-recordati-epar-product-information_et.pdf)

ελληνικά (EL) (547.28 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/el/documents/product-information/silodosin-recordati-epar-product-information_el.pdf)

français (FR) (433.74 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/fr/documents/product-information/silodosin-recordati-epar-product-information_fr.pdf)

hrvatski (HR) (489.68 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/hr/documents/product-information/silodosin-recordati-epar-product-information_hr.pdf)

íslenska (IS) (415.78 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/is/documents/product-information/silodosin-recordati-epar-product-information_is.pdf)

italiano (IT) (419.39 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/it/documents/product-information/silodosin-recordati-epar-product-information_it.pdf)

latviešu valoda (LV) (483.55 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/lv/documents/product-information/silodosin-recordati-epar-product-information_lv.pdf)

lietuvių kalba (LT) (493.25 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/lt/documents/product-information/silodosin-recordati-epar-product-information_lt.pdf)

magyar (HU) (474.54 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/hu/documents/product-information/silodosin-recordati-epar-product-information_hu.pdf)

Malti (MT) (532.61 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/mt/documents/product-information/silodosin-recordati-epar-product-information_mt.pdf)

Nederlands (NL) (424.64 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/nl/documents/product-information/silodosin-recordati-epar-product-information_nl.pdf)

norsk (NO) (409.26 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/no/documents/product-information/silodosin-recordati-epar-product-information_no.pdf)

polski (PL) (517.47 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/pl/documents/product-information/silodosin-recordati-epar-product-information_pl.pdf)

português (PT) (419.24 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/pt/documents/product-information/silodosin-recordati-epar-product-information_pt.pdf)

română (RO) (515.06 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/ro/documents/product-information/silodosin-recordati-epar-product-information_ro.pdf)

slovenčina (SK) (602.37 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/sk/documents/product-information/silodosin-recordati-epar-product-information_sk.pdf)

slovenščina (SL) (489.49 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/sl/documents/product-information/silodosin-recordati-epar-product-information_sl.pdf)

Suomi (FI) (409.77 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/fi/documents/product-information/silodosin-recordati-epar-product-information_fi.pdf)

svenska (SV) (404.79 KB - PDF)

**First published:**

22/01/2019

**Last updated:**

10/03/2025

[View](/sv/documents/product-information/silodosin-recordati-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000255260 10/03/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Silodosin Recordati : EPAR - All authorised presentations

English (EN) (19.67 KB - PDF)

**First published:** 22/01/2019

[View](/en/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-543)

български (BG) (68.34 KB - PDF)

**First published:**

22/01/2019

[View](/bg/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_bg.pdf)

español (ES) (20.84 KB - PDF)

**First published:**

22/01/2019

[View](/es/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_es.pdf)

čeština (CS) (28.44 KB - PDF)

**First published:**

22/01/2019

[View](/cs/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (20.29 KB - PDF)

**First published:**

22/01/2019

[View](/da/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (19.25 KB - PDF)

**First published:**

22/01/2019

[View](/de/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (19.69 KB - PDF)

**First published:**

22/01/2019

[View](/et/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (43.55 KB - PDF)

**First published:**

22/01/2019

[View](/el/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_el.pdf)

français (FR) (20.93 KB - PDF)

**First published:**

22/01/2019

[View](/fr/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (31.78 KB - PDF)

**First published:**

22/01/2019

[View](/hr/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (18.75 KB - PDF)

**First published:**

22/01/2019

[View](/is/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_is.pdf)

italiano (IT) (18.13 KB - PDF)

**First published:**

22/01/2019

[View](/it/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (50.19 KB - PDF)

**First published:**

22/01/2019

[View](/lv/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (52.18 KB - PDF)

**First published:**

22/01/2019

[View](/lt/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (34.58 KB - PDF)

**First published:**

22/01/2019

[View](/hu/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (48.75 KB - PDF)

**First published:**

22/01/2019

[View](/mt/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (18.37 KB - PDF)

**First published:**

22/01/2019

[View](/nl/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (19.91 KB - PDF)

**First published:**

22/01/2019

[View](/no/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_no.pdf)

polski (PL) (51.5 KB - PDF)

**First published:**

22/01/2019

[View](/pl/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_pl.pdf)

português (PT) (17.8 KB - PDF)

**First published:**

22/01/2019

[View](/pt/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_pt.pdf)

română (RO) (49.2 KB - PDF)

**First published:**

22/01/2019

[View](/ro/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (31.36 KB - PDF)

**First published:**

22/01/2019

[View](/sk/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (30.7 KB - PDF)

**First published:**

22/01/2019

[View](/sl/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (20.9 KB - PDF)

**First published:**

22/01/2019

[View](/fi/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (20.07 KB - PDF)

**First published:**

22/01/2019

[View](/sv/documents/all-authorised-presentations/silodosin-recordati-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Silodosin Recordati Active substance silodosin International non-proprietary name (INN) or common name silodosin Therapeutic area (MeSH) Prostatic Hyperplasia Anatomical therapeutic chemical (ATC) code G04CA04

### Pharmacotherapeutic group

- Urologicals
- Alpha-adrenoreceptor antagonists

### Therapeutic indication

Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult men.

## Authorisation details

EMA product number EMEA/H/C/004964

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Recordati Ireland Ltd

Raheens East

Marketing authorisation issued 07/01/2019 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Silodosin Recordati : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (140.46 KB - PDF)

**First published:** 18/11/2021

**Last updated:** 10/03/2025

[View](/en/documents/procedural-steps-after/silodosin-recordati-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Silodosin Recordati : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/845183/2018

English (EN) (198.22 KB - PDF)

**First published:** 22/01/2019

[View](/en/documents/assessment-report/silodosin-recordati-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Silodosin Recordati

Adopted

Reference Number: EMA/766073/2018

English (EN) (73.33 KB - PDF)

**First published:** 16/11/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-silodosin-recordati_en.pdf)

#### News on Silodosin Recordati

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018) 16/11/2018

#### More information on Silodosin Recordati

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 10/03/2025

## Share this page

[Back to top](#main-content)